Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1318-1320

  Lancioni, Christina ^a   LaBeaud, A Desiree ^a   Esper, Frank ^a   Abughali, Nazha ^b   Auletta, Jeffery ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Immunosuppression; Leukemia; Mycobacterium tuberculosis; Pediatric

Indexed keywords

AMPHOTERICIN B; AZITHROMYCIN; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETHAMBUTOL; ISONIAZID; PIPERACILLIN PLUS TAZOBACTAM; PYRAZINAMIDE; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN; VINCRISTINE; ANTINEOPLASTIC AGENT; TUBERCULOSTATIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAMNESIS; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FOLLOW UP; HUMAN; LUNG BIOPSY; LUNG LOBECTOMY; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; CONTACT EXAMINATION; DISEASE TRANSMISSION; DRUG COMBINATION; IMMUNE DEFICIENCY; ISOLATION AND PURIFICATION; LUNG RESECTION; MULTIMODALITY CANCER THERAPY; PYREXIA IDIOPATHICA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITUBERCULAR AGENTS; AZITHROMYCIN; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CONTACT TRACING; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEVER OF UNKNOWN ORIGIN; HUMANS; IMMUNOCOMPROMISED HOST; ISONIAZID; LYMPHOPENIA; MALE; MYCOBACTERIUM TUBERCULOSIS; PNEUMONECTOMY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY; VINCRISTINE;

EID: 70449723310     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22155     Document Type: Article

References (22)

1. US Department of Health and Human Services. Reported tuberculosis in the United States, 2004. Available at: http://wonder.cdc.gov/tb.html. Accessed 2 May 2007.
2. Nelson LJ, Schneider E, Wells CD, et al. Epidemiology of childhood tuberculosis in the United States, 1993-2001: The need for continued vigilance. Pediatrics 2004;114:333-341.
3. Kaplan M, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease: A review of 201 cases. Cancer 1974;33:850-858.
4. De la Rosa GR, Jacobson KL, Rolston KV, et al. Mycobacterium tuberculosis at a comprehensive cancer centre: Active disease in patients with underlying malignancy during 1990-2000. Clin Microbiol Infect 2004;10:749-752.
5. Kamboj M, Sepkowitz K. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006;42:1592-1595.
6. Khan B, Ahmed P, Ullah K, et al. Frequency of tuberculosis in haematological malignancies and stem cell transplant recipients. J Coll Phys Surg Pak 2005;15:30-33.
7. Chan L, Loeffler A. Fever cough and pneumonia in a patient with acute lymphocytic leukemia. Pediatr Infect Dis 1997;16:1013-1014.
8. Choudhry VP. Pulmonary tuberculosis in children with acute lymphatic leukemia. Indian J Pediatr 1981;48:117-119.
9. Klossek A, Dannenberg C, Feuerhahn MR, et al. Pulmonary tuberculosis in a child receiving intensive chemotherapy for acute myeloblastic leukemia. J Pediatr Hematol Oncol 2004;26:64-67.
10. Dannenberg A. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis 1989;11:S369-S377.
11. Fauci AS. Immunosuppressive and anti-inflammatory effects of glucocorticoids. Monogr Endocrinol 1979;12:449-465.
12. Cordani S, Manna A, Vignali M, et al. Bronchoalveolar lavage as a diagnostic tool in patients with haematological malignancies and pneumonia. Le Infezioni Med 2008;4:209-213.
13. Hofmeyr A, Lau WF, Slavin MA. Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberculosis 2007;87:459-463.
14. Taylor Z. Guidelines for the investigation of contacts of persons with infectious tuberculosis. MMWR 2005;54:1-37.
15. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009 [Epub ahead of print]. 10.1378/chest:08-2575.
16. Piana F, Codecasa LR, Cavallerio P. et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006;28:31-34.
17. Lighter J, Rigaud M, Eduardo R, et al. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB Gold In-Tube test. Pediatrics 2009;123:30-37.
18. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003;361:1168-1173.
19. Kim D, Lee S, Yoo CG, et al. Clinical characteristics and treatment response of tuberculosis patients with malignancy receiving anticancer chemotherapy. Chest 2005;128:2218-2222.
20. Dautzenberg B, Grosset J, Fechner J, et al. The management of thirty immunocompromised patients with tuberculosis. Am Rev Respir Dis 1984;129:494-496.
21. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world, fourth global report. 2002-2007. WHO/HTM/TB/2008.394.
22. Committee on Infectious Diseases, American Academy of Pediatrics. Tuberculosis. In: Pickering LK, Baker C, Long S, McMillan J, editors. Red Book: 2006 report of the committee on infectious diseases, 27th edition. American Academy of Pediatrics; 2006. pp. 678-698.